ASH Conference Coverage
Featured News
(BioPharma Dive) Dec 5, 2018 - Like many a medical meeting, ASH showcased data that — while promising — also offers as many questions as answers. With another American Society of Hematology meeting in the books, the industry can take a minute to appreciate the notable advances seen in San Diego earlier this week. A new...
(BioPharma Dive) Dec 5, 2018 - In drugmakers' quest to coax immune cells to attack cancer, two might turn out to be better than one. Recent advances in cancer therapeutics have centered on the might of the body's defenders to recognize and kill tumor cells. Seeking to help the immune system "see" cancers, researchers have turned to...
(ASH) Dec 4, 2018 - Three studies being presented today during the 60th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego offer more targeted solutions for managing CLL and multiple myeloma. “The most important take home point is that all three of these late-breaking studies demonstrate how targeted...
(NCI) Dec 4, 2018 - An interim analysis of a large phase 3 clinical trial found that the combination of ibrutinib plus rituximab was superior to standard treatment for patients age 70 and younger with previously untreated chronic lymphocytic leukemia (CLL). The trial met its primary endpoint of an improvement in progression-free...
(Reuters) Dec 4, 2018 - Johnson & Johnson’s blockbuster blood cancer drug Darzalex significantly reduced the risk of disease progression or death in patients who have not been previously treated for multiple myeloma, late-stage study data showed on Tuesday. The injection when used with standard of care drugs, Celgene Corp’s...
(Xconomy National) Dec 4, 2018 - The treatment landscape for multiple myeloma, a deadly cancer of the bone marrow that affects about 30,000 Americans every year, has changed significantly over the past decade. And more changes look to be on the way. Take the results of a Phase 3 study just reported today at the American Society of...
(Xconomy National) Dec 3, 2018 - Last week, Xconomy previewed the American Society of Hematology’s big meeting in San Diego, the largest medical gathering in the country on blood diseases. We took a deep dive into five specific disease areas under scrutiny, from lymphoma to hemophilia to sickle cell disease and more. News related...
(bluebird bio) Dec 2, 2018 - bluebird bio, Inc. and Celgene Corporation announced initial data from the ongoing Phase 1 clinical study of bb21217 (CRB-402), an investigational next-generation anti-BCMA CAR T cell therapy being studied in patients with relapsed/refractory multiple myeloma. The data were presented by Nina Shah, M.D.,...
(Bloomberg) Dec 3, 2018 - CAR-T therapies were heralded as one-time cures for some dire cases. Many patients, it turns out, relapse over time after a complete remission. Shahzad Bhat, 53, was working as a bartender for elite gamblers at the MGM Mansion in Las Vegas when his doctor gave him three months to live in October 2017. There...
(Reuters) Dec 3, 2018 - Roche’s Hemlibra provided sustained bleed control in the largest pivotal study to date of children with a form of haemophilia, the Swiss drugmaker said on Monday. Nearly 77 percent of children receiving Hemlibra once weekly experienced no treated bleeds, while Hemlibra once weekly reduced treated bleeds by 99...
(The Business Journals) Dec 2, 2018 - Celgene Corporation and Acceleron Pharma Inc. today announced results from the pivotal, phase 3 MEDALIST trial evaluating the efficacy and safety of investigational luspatercept to treat patients with ring sideroblast (RS+) myelodysplastic syndromes (MDS)-associated anemia who require red blood cell...
(MD Anderson) Dec 2, 2018 - A follow-up analysis of patients enrolled in a Phase I/II multi-center trial for diffuse large B-cell lymphoma (DLBCL) reported 51 percent of patients receiving an anti-CD19 chimeric antigen receptor (CAR T) called axi-cel were still alive two years post-treatment. The study, co-led by Sattva Neelapu,...
(ASH 2018) Dec 1, 2018 - Chimeric antigen receptor (CAR) T-cell therapies have quickly shifted the treatment paradigm for many people with several types of aggressive blood cancers, in whom treatment options have been woefully limited. Five studies being presented today at the 60th American Society of Hematology (ASH) Annual Meeting...
(ASH 2018) Dec 1, 2018 - Today during the 60th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, researchers will present the results of four large trials that evaluate promising new treatment options for patients with several types of malignant and non-cancerous blood disorders. “These studies will...
(Cardinal Health) Nov 30, 2018 — Oncologists are growing more confident in their ability to meet the requirements of the Medicare Access & CHIP Reauthorization Act (MACRA), according to new research from Cardinal Health Specialty Solutions. These findings were released today in the fourth edition of Oncology Insights, a...
(ASH) Nov 28, 2018 - Researchers have developed a way to grow human platelets in the laboratory from stem cells derived from fat tissue, suggesting manufactured platelets could eventually reduce the reliance on donated platelets to help patients with cancer and other disorders. Platelets are a component of blood that helps with...
View all
More News
(UW School of Medicine) Dec 5, 2018 - Advances in rapid screening of leukemia cells for drug susceptibility and resistance are bringing scientists closer to patient-tailored treatment for acute myeloid leukemia (AML).
(BioPharma Dive) Dec 6, 2018 - Swiss pharma Novartis says it has made progress remedying production issues that have hampered commercial roll-out of its cancer cell therapy Kymriah in lymphoma.
(BioPharma Dive) Dec 5, 2018 - The field of CAR-T therapy took major steps forward this week at the American Society of Hematology's annual conference — but one big question still looms.
(BeyondSpring) Dec 6, 2018 - BeyondSpring Inc. today announced that the Phase 3 portion of its pivotal Study 105, evaluating its lead asset, Plinabulin, in the 105 enrolled patients treated with docetaxel chemotherapy, has met its primary endpoint of non-inferiority versus Neulasta® for the duration of severe neutropenia (DSN) of the...
(Morningstar) Dec 6, 2018 - Stemline Therapeutics, Inc. presented updated data from multiple ELZONRISTM (tagraxofusp; SL-401) clinical trials at the 2018 ASH Annual Meeting.
(Dana-Farber) Dec 3, 2018 - Dana-Farber Cancer Institute scientists will present research marking significant advances against the hematologic cancer multiple myeloma at the American Society of Hematology (ASH) Annual Meeting Dec. 1-4. Their findings provide new insights into the progression of the disease from precursor conditions and...
(Reuters) Dec 3, 2018 - Amgen Inc, updating the first trial of its bispecific antibody for multiple myeloma, said on Monday seven out of 10 patients given the second-highest dose of AMG420 responded to the drug, including four with no detectable cancer. Six patients were still responding at 7.5 months of follow-up, according to...
(ASH) Dec 2, 2018 - The American Society of Hematology (ASH) will recognize three Choosing Wisely® Champions, practitioners working to tackle overuse of hematology tests and treatments, today at its 60th annual meeting in San Diego.
(MarketWatch) Dec 3, 2018 - Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced that data from the ECHELON-2 phase 3 clinical trial will be presented today in an oral session at the 60[th] American Society of Hematology (ASH) Annual Meeting. The data demonstrated that frontline treatment with ADCETRIS...
(Morningstar) Dec 3, 2018 - Celgene Corporation today announced initial safety data from its ongoing proof-of-concept trial of JCARH125 in patients with relapsed/refractory multiple myeloma. JCARH125 is an investigational BCMA-targeting CAR T cell therapy being developed by Juno Therapeutics, A Celgene Company. Results were presented by...
(Seeking Alpha) Dec 3, 2018 - Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, today announced presentations highlighting updated data from the Phase 2b STORM study evaluating selinexor, the Company’s first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, in patients with penta-refractory...
(Legend Biotech) Dec 3, 2018 - Legend Biotech reported updated data on the LEGEND-2 Phase 1/2 open-label study, which evaluated the investigational chimeric antigen receptor T-cell (CAR-T) therapy LCAR-B38M in the treatment of patients with advanced relapsed or refractory (R/R) multiple myeloma. The findings, featured in an oral...
Featured Videos
There are no featured ASH Conference Coverage videos.

OBR Tweets

Jul 09
H. Jack West, MD: The benefit of low dose chest CT screening for lung cancer remains somewhat controversial, but th… https://t.co/8wOgsSCY7q

Jul 08
Howard S. Hochster, MD: While a "complete response" is great for our patients, the Complete Response Letter was les… https://t.co/yQGkfvpMCF

Jul 02
A panel of three breast cancer experts looked at some of the big studies at #ASCO20 and discussed treatment advance… https://t.co/ve0XD0cWDY

Jul 01
A report on several promising studies at #ASCO20 focused on personalized therapies for patients with unmet needs. I… https://t.co/lc4BoQ3Evl

Jul 01
At #ASCO’s virtual meeting, studies featured potentially practice-changing data. Among the studies were the BOSTON… https://t.co/6pXpxFomwu

Jun 22
Howard S. Hochster, MD: Another, but far more problematic approval for Pembro. Which tumors actually have high TMB… https://t.co/pBSquns9mN

Jun 19
Dean Gesme, MD: The positive primary endpoint of improved iDFS with Abemaciclib plus adjuvant AI in this Monarch E… https://t.co/GXnYhO8jov

Jun 17
Thomas Marsland, MD: I actually enjoyed the experience. I certainly missed mingling with friends and colleagues. Al… https://t.co/gVtYjkzPzy

Jun 16
Derek Raghavan, MD, on @LevineCancer provides a general overview of prostate cancer therapies #ASCO20 https://t.co/niwz0yPHjB

Jun 16
H. Jack West, MD: We await phase 3 data, but many will welcome a new option with an approximately 35% response rate… https://t.co/Ld5N8KrWye